Patents Examined by Amber D. Steele
  • Compositions and methods for using actin-based peptides to modulate cellular bioactivity and cellular susceptibility to intracellular pathogens
    Patent number: 11028138
    Abstract: Compositions and methods for using actin-based peptides to modulate cellular bioactivity, including modulation of cellular susceptibility to intracellular pathogens, such as bacteria and viruses.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: June 8, 2021
    Inventor: Yuntao Wu
  • Compositions for expanding regulatory T cells (Treg) populations, and treating and ameliorating autoimmune diseases and conditions
    Patent number: 11028129
    Abstract: In alternative embodiments, provided are compositions, including e.g., isolated, synthetic or recombinant peptides or polypeptides, for: expanding regulatory T cells (Treg) populations; or, for treating, ameliorating, preventing or reversing a vascular inflammation, and Kawasaki disease (KD) or a pediatric acute vasculitis of the coronary arteries, including vascular coronary abnormalities and the same or similar types of acute or chronic vascular inflammatory abnormalities, and methods for making and using them.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: June 8, 2021
    Assignee: The Regents of the University of California
    Inventor: Alessandra Franco
  • Composition having tissue-repairing activity, and use therefor
    Patent number: 11000572
    Abstract: A composition having tissue repair activity, which is capable of promoting reactions associated with tissue repair, contains at least one selected from the group consisting of a first component that is a protein having a monocyte chemotactic protein-1 (MCP-1) activity, a second component that is a protein having the extracellular domain activity of sialic acid-binding immunoglobulin-type lectin-9 (Siglec-9), and a third component that is at least one of chondroitin sulfate and chondroitin sulfate proteoglycan.
    Type: Grant
    Filed: November 1, 2019
    Date of Patent: May 11, 2021
    Assignee: TOKUSHIMA UNIVERSITY
    Inventors: Akihito Yamamoto, Minoru Ueda, Kohki Matsubara, Akio Suzumura, Koichi Furukawa, Yoshihiro Matsushita, Hirotaka Wakayama, Nobunori Takahashi, Shin Tsunekawa, Takako Izumoto
  • Methods of treating acute myeloid leukemia
    Patent number: 10993985
    Abstract: A method of treating acute myeloid leukemia (AML), including the steps of (i) measuring a density of blast cells in the peripheral blood and the bone marrow of a subject with AML; (ii) administering to the subject a CXCR4 antagonist; and (iii) administering to the subject a therapeutically effective amount of the CXCR4 antagonist and a therapeutically effective amount of a chemotherapeutic agent, if the blast cell density in the peripheral blood is less than 10% of the total peripheral white blood cells, or at least five-fold lower than the blast cell density in the bone marrow, or at least two-fold higher one day or more following step (ii).
    Type: Grant
    Filed: February 23, 2017
    Date of Patent: May 4, 2021
    Assignees: BioLmeRx Ltd., Biokine Therapeutics Ltd.
    Inventors: Yaron Pereg, Amnon Peled
  • Proteolically resistant cyclotides with angiotensin 1-7 like activity
    Patent number: 10988522
    Abstract: Described herein is a novel cyclotide able to activate the unique receptor of angiotensin-(1-7) (AT1-7), the MAS1 receptor. This cyclotide may be used in the treatment of cancer and myocardial infarction.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: April 27, 2021
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Julio A. Camarero Palao, Teshome L. Aboye, Kathleen E. Rodgers
  • Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules
    Patent number: 10980893
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: April 20, 2021
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Maurits Kleijnen, Meidai Sun
  • Reduced oxygen carriers and their use for the treatment of carboxyhemoglobinemia
    Patent number: 10973883
    Abstract: In vitro and in vivo methods of removing carbon monoxide from hemoglobin in blood or animal tissue are described. Methods of treating carboxyhemoglobinemia (carbon monoxide poisoning) in a subject are also described. The methods include administering natural or artificial oxygen carriers that are in their reduced form. Methods of producing a reduced oxygen carrier are further described. Methods of treating cyanide poisoning or hydrogen sulfide poisoning with oxygen carriers are also described.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: April 13, 2021
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Jason Joseph Rose, Qinzi Xu, Mark T. Gladwin, Jesus Tejero Bravo
  • Target recognition motifs and uses thereof
    Patent number: 10968257
    Abstract: The disclosure provides novel programmable targeting sequences and applications thereof. The targeting sequences can be engineered for binding to proteins, polypeptides, and other macromolecules.
    Type: Grant
    Filed: April 3, 2019
    Date of Patent: April 6, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventor: Feng Zhang
  • Methods and compositions for treating NAFLD, hepatic steatosis, and sequelae thereof
    Patent number: 10967051
    Abstract: Provided herein are oral pharmaceutical compositions containing a GLP-1 analogue and/or insulin for treating and reducing the incidence of nonalcoholic fatty liver disease (NAFLD), hepatic steatosis, and sequelae thereof, and methods of utilizing same.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: April 6, 2021
    Assignee: Oramed Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Conductive yarn
    Patent number: 10964443
    Abstract: An electrically conductive yarn or film and method of manufacturing thereof in which a SP1/nanoparticle complex bound to the yarn or film serves as a platform for adhesion of a metallic coating.
    Type: Grant
    Filed: January 29, 2017
    Date of Patent: March 30, 2021
    Assignee: SP Nano Ltd.
    Inventors: Konstantin Press, Asa Eitan, Tamir Fine, Michael Kaminsky, Amnon Wolf
  • Small molecules blocking histone reader domains
    Patent number: 10961289
    Abstract: The present invention relates to small molecules interfering with the conformational space of the TONSL ARD occupied by the histone H4 tail. These small molecules targets the binding pocket of TONSL encompassing the H4 residues K12-R23 and act by preventing or disrupting the binding of the H4 tail K12-R23 with the TONSL ARD via direct competition or via allosteric disruption of the binding pocket.
    Type: Grant
    Filed: November 29, 2019
    Date of Patent: March 30, 2021
    Assignees: The University of Copenhagen, Memorial Sloan-Kettering Cancer Center
    Inventors: Anja Groth, Giulia Saredi, Hongda Huang, Colin Hammond, Dinshaw Patel
  • Composition comprising SP1 and carbon based nanoparticles and uses thereof
    Patent number: 10954313
    Abstract: The present invention, relates to composition of matter comprising sequence variants of Stable Protein 1 (SP1) and carbon nanotubes or carbon black, and optionally comprising latex. This invention also relates to surfaces (e.g. metal wires, cords, and polymeric and non polymeric fibers, yarns, films or fabrics, wood and nano, micro and macro particles) comprising this composition of matter, to methods for producing them, and to uses thereof in the preparation and formation of improved composite materials, including rubber, and rubber compound composites.
    Type: Grant
    Filed: January 29, 2017
    Date of Patent: March 23, 2021
    Assignee: SP Nano Ltd.
    Inventors: Asa Eitan, Yana Tesler, Jeanie Tamir, Nurit Shalev, Leonid Melekhov, Oshrit Poliker, Amnon Wolf, Konstantin Press
  • Peptides derived from transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to MHC molecules
    Patent number: 10946105
    Abstract: The present invention relates to novel peptides derived from Transient receptor potential cation channel subfamily M member 1 (TRPM1), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: March 16, 2021
    Assignee: IMMUNOCORE LIMITED
    Inventors: Alex Powlesland, Maurits Kleijnen, Meidai Sun
  • Functionalized protein-based materials and their uses
    Patent number: 10947282
    Abstract: Embodiments of the invention are directed to Ubx-fusion molecules that maintain their mechanical strength and properties even after being fused with Ubx. Ubx fusions with VEGF and other growth factors, cell signaling proteins, and cell binding proteins can be used to induce angiogenesis. Ubx fibers and mesh, embedded within a tissue engineering scaffold, induce formation of vasculature within the scaffold. The presence of vasculature is necessary to provide oxygen and nutrients to other cells growing within the scaffold.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: March 16, 2021
    Assignees: The Texas A & M University System, William Marsh Rice University
    Inventors: Sarah Bondos, Kayla Bayless, Kathleen Matthews, Jan Patterson, Colette Abbey, David Howell, Hao-Ching Hsiao, Kelly Churion, Shang-Pu Tsai, Sandhya Ramasamy, Dustin Porterpan, Keira Northern
  • Core domain of annexins and uses thereof in antigen delivery and vaccination
    Patent number: 10947283
    Abstract: The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, e.g., which include an annexin core domain to mediate efficient antigen delivery and antigen presentation in order to induce an antigen-specific immune response and/or to treat or prevent infectious diseases and/or cancer.
    Type: Grant
    Filed: June 8, 2017
    Date of Patent: March 16, 2021
    Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS
    Inventors: Fatmire Bujupi, Peter Krammer, Heiko Weyd
  • Peptides for angiogenic therapy
    Patent number: 10934334
    Abstract: Provided herein are compositions including peptide or nucleic acids encoding peptides and related methods for the treatment of angiogenic conditions such as cancer, vascular disorders such as cardiovascular disorders, and infectious disease.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: March 2, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: Mira Sastri
  • Separation of VWF and VWF propeptide by chromatographic methods
    Patent number: 10934340
    Abstract: The present invention relates to a method for separating a mature von Willebrand Factor (mat-VWF) from von Willebrand Factor pro-peptide (VWF-PP) by incubating a composition comprising inducing dissociation of mat-VWF and VWF-PP by disruption of the non-covalently associated mat-VWF and VWF-PP, wherein said dissociation is induced by: (i) addition of at least one chelating agent, or (ii) increasing the pH to a pH of at least 7, and then collecting said mat-VWF to obtain a high purity, propeptide depleted mature VWF (mat-VWF).
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: March 2, 2021
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Christian Fiedler, Meinhard Hasslacher, Christa Mayer
  • Rapid-acting insulin compositions
    Patent number: 10925931
    Abstract: The invention is a pharmaceutical composition of human insulin or insulin analog that includes citrate, treprostinil and stabilizing agents, that has faster pharmacokinetic and/or pharmacodynamic action than commercial formulations of existing insulin analog products and that is stable for commercial use.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: February 23, 2021
    Assignee: Eli Lilly and Company
    Inventors: Michael Patrick Akers, Michael Edward Christe, Thomas Andrew Hardy, Ranajoy Majumdar, Chi Arch Nguyen, Chad Donald Paavola, Virender Kumar Sarin, Nanette Elizabeth Schulte
  • Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta
    Patent number: 10927155
    Abstract: In one aspect, the invention relates to compositions comprising peptides and/or peptidomimetic compounds, methods of making same, pharmaceutical compositions comprising same, and methods of treating various diseases, including, but not limited to, arthritis, obstructive lung disease, psoriasis, asthma, a defect in hematopoiesis, a neoplasia, a fungal infection, a parasitic infection, or an autoimmune disease, such as, but not limited to, rheumatoid arthritis, atopic allergy, anaphylaxis, psoriasis, asthma, lupus erythematosis, a myeloid cell disorder, or a eosinophil cell disorder. In an aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the ST2 and IL33 receptor/cytokine complexes. In a further aspect, the disclosed peptides and/or compounds inhibit the interaction of IL-1RAcP with the IL-1R1 and IL-1? receptor/cytokine complexes.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: February 23, 2021
    Assignee: GEORGE MASON RESEARCH FOUNDATION, INC.
    Inventors: Lance Liotta, Alessandra Luchini, Virginia Espina, Mikell Paige
  • Peptide nanoparticles and uses therefor
    Patent number: 10905637
    Abstract: The present invention provides nanoparticle compositions including one or more peptides. The present invention achieves transdermal delivery of such peptides without the need for peptide modification, or for use of chemical or mechanical abrasion or disruption of skin.
    Type: Grant
    Filed: September 29, 2016
    Date of Patent: February 2, 2021
    Assignee: Anterios, Inc.
    Inventors: Jonathan Edelson, Timothy Kotyla